The American Cancer Society predicts 1 in 8 men will be diagnosed with prostate cancer in their lifetime.

A new study by the Medical University of Vienna found that a specialized form of imaging could identify 91% of prostate cancer cases without the need for a biopsy. Traditionally, a blood test can ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and SOPHiA GENETICS (NASDAQ: SOPH) today announce a collaboration to advance new prostate ...

"The number of men living with prostate cancer also continues to rise, so it's vital that we see investment in prostate ...

SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new ...

As the standards of care for prostate cancer change, new drugs, combination therapies, and trials enter the therapeutic space ...

Prostate cancer is the second most commonly diagnosed cancer among men worldwide, with an estimated 1.55 million new cases in ...

CHAPS, the leading prostate screening charity, is holding a unique workshop aiming to tackle the conflicting messages men are ...

Researchers have identified a change in the way cells make proteins that may help prostate cancer become more aggressive and resist treatment. The finding points to a possible vulnerability in cancers ...

I reject the idea that a man who keeps every prostate cancer surveillance appointment has ‘untreated cancer,’” writes Howard ...

A new review in Medical Oncology details how liquid biomarkers, advanced imaging, and artificial intelligence are transforming pre-biopsy discrimination of prostate cancer from benign disease.

A new rat study shows the immunosuppressant mycophenolate mofetil dismantles prostate stromal fibers in two timed phases, ...